2-FA

The legacy wording is corrected to the canonical status prohibited and the acronym is resolved from the official chemical entry rather than inferred. The Shenzhen Public Security Bureau's 17 July 2026 controlled-drug directory (stated current as of 1 July 2026) reproduces the 2025 non-medicinal directory and expressly lists 2-FA as item 12, while separately listing 2-FMA as item 13. The 2026 three-department announcement added 16 other substances effective 1 July 2026; it does not replace the 2-FA entry. The current State Council regulation defines controlled narcotic/psychotropic substances by directory inclusion and states that non-medicinal controlled substances may be used only for approved research under the regulation and may not be produced, operated, used, stored or transported; the 2015 implementing measure also expressly prohibited production, sale, transport, use, storage and import/export. The Anti-Drug Law and Criminal Law define drugs to include other state-controlled addictive narcotic and psychotropic substances. Criminal Law article 347 provides conduct- and quantity-dependent penalties for smuggling, selling, transporting or manufacturing drugs, beginning at up to three years for small quantities and reaching 15 years, life imprisonment or death plus confiscation in aggravated cases; article 348 addresses illegal possession. Article 84 of the national Public Security Administration Punishments Law, as reproduced in Beijing's 2026 police guidance, provides 10–15 days' detention and up to RMB 3,000 fine for illegal possession, provision or use of drugs, with lesser-case alternatives. These penalties are not a 2-FA-specific sentencing prediction.

The legacy wording is corrected to the canonical restricted_other status and the official lower-case category name Verzeichnis e. The current consolidated BetmVV-EDI expressly names 2-FA and supplies its chemical designation in Annex 6 item 12. BetmVV-EDI Articles 1(2)(a) and 2(2) make Annex 1–6 entries controlled substances and place Verzeichnis e in Annex 6. BetmKV Article 3(2)(e) subjects Verzeichnis-e entries to the control measures applicable to Verzeichnis-a narcotics, while Article 5(2) assigns operating permits for handling Verzeichnis-e substances to the EDI and Article 11(1) requires an operating permit for listed handling activities including manufacture, obtaining, brokering, import/export, supply and trade. BetmG Article 7(1) requires EDI authorization and compliance with its conditions for cultivating, manufacturing, importing, exporting, storing, using or placing Article 7 materials/products into circulation; Article 20(1)(c) provides up to three years' imprisonment or a monetary penalty for specified unauthorized conduct involving Article 7 substances and products. These sources support a permit-based restricted_other classification, not an assertion that 2-FA is in Verzeichnis d or that every possible act is categorically prohibited. No separate 2-FA-specific exemption was located in the inspected item-12 text, so none is asserted.

The identity route is direct: NIH PubChem CID 121531 identifies 2-Fluoroamphetamine as 1-(2-fluorophenyl)propan-2-amine and lists 2-FA, o-fluoro-alpha-methylphenethylamine and CAS 1716-60-5 as synonyms. Finlex’s official 153/2025 amendment replaces Appendix II and took effect on 25 April 2025; its List I text expressly includes 2-Fluoriamfetamiini (2-FA) with the o-fluoro-α-methylphenethylamine designation. The latest inspected amendment to Decree 543/2008, 651/2026, took effect on 10 July 2026 and amends only Appendices I, III and IV (not Appendix II), so the Appendix II entry remains the current inspected schedule basis as of 28 August 2026. Narcotics Act 373/2008 section 3(1)(5)(b) covers 1971 Convention Lists I–IV, section 3(2) provides that the detailed substances are set by Government decree, and section 5 prohibits the listed handling activities subject to statutory exceptions. Criminal Code Chapter 50 section 1 provides a fine or imprisonment of at most two years for illegal manufacture, import/export/transport, distribution or possession/acquisition of a narcotic drug; section 2 provides imprisonment of one to ten years for an aggravated narcotics offence when one of the listed aggravating circumstances applies and the offence is aggravated as a whole. Penalties are conduct-specific and do not mean that every possession or use receives the maximum sentence. No separate Finnish medicine authorization for 2-FA was asserted; the inspected sources establish narcotics scheduling and criminal provisions, not a medicine marketing authorization.

As of 28 August 2026, the strongest official evidence supports correcting the legacy generic 'Illegal' entry to the canonical status prohibited. The decisive substance-specific record is the official Emniyet Genel Müdürlüğü/TUBİM Türkiye Uyuşturucu Raporu 2014: under 'EK-2' it identifies Bakanlar Kurulu decision 2013/5742 (dated 16 December 2013 and published 25 January 2014 in Official Gazette No. 28893) and item 45 expressly reads '2. 2-FA ... 1-(2-fluorophenyl)propan-2-amine' (the report's numbered entry is item 45). The current Narkotik Suçlarla Mücadele Başkanlığı mandate page says that necessary new psychoactive substances are brought under Law No. 2313 through the EWS process and that the generic-classification system brings many synthetic derivatives under the law. The official 2025 Türkiye Drug Report states that 1,078 NPS had been brought under Law No. 2313 by 31 July 2025 and that generic classification had been used since 2015, confirming that the 2313/EWS framework remained operative in the latest inspected national report; it does not report a repeal of the 2013/5742 entry. The current official TCK text supplies the conduct-specific controls: Article 188(1) sets 20–30 years plus a judicial fine for unauthorized manufacture/import/export; Article 188(3) sets at least 10 years plus a judicial fine for unauthorized domestic sale, offer, giving, dispatch, transport, storage, purchase, acceptance or possession (at least 15 years where the recipient is a child); Article 188(4)(a) expressly names amphetamine and derivatives; and Article 191(1) sets 2–5 years for purchase, acceptance or possession for use or use, with the postponement/probation framework in Article 191(2)–(3). The current sources do not establish a licensed therapeutic product or prescription exception for 2-FA, so it is not characterized as prescription_only.